News | May 02, 2024
Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
A game changing solution for the pharmaceutical industry
The company plans to add 1700 beds by FY27 through the organic route
Subscribe To Our Newsletter & Stay Updated
